METTL14 and chronic myelogenous leukemia, BCR-ABL1 positive: Another study reported that downregulation of METTL3 and METTL14 decreased imatinib resistance in chronic myelogenous leukemia (CML), thus, inhibitors of METTL3/METTL14 complexes could be a new approach to rescue TKI resistance [63].